SHR2554 not checked

Hengrui · EZH2 Inhibitor

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
6 active
13 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days”In the company’s words, NCT07175220 on ClinicalTrials.gov
Tested for
Prostate Cancer (2 trials), Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Follicular Lymphoma, Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Main trialPhase 3
“This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.”In the company’s words, NCT06122389 on ClinicalTrials.gov
Other names
EZH2 Inhibitor

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2026 SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 2Not yet recruiting Apr 2027 A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 2Recruiting Dec 2027 Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Phase 2Recruiting Oct 2028 Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Phase 2Recruiting Dec 2028 A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Phase 1/2Recruiting Dec 2026 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Phase 1/2Terminated 30 Sep 2019 A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Phase 1Unknown 6 Jan 2022 A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
Phase 1Completed 14 Dec 2022 Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
Phase 1Completed 31 Mar 2023 Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Phase 1Completed 27 Nov 2023 A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers
Phase 1Completed 29 Nov 2023 Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Phase 1Unknown 14 Feb 2026 A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SHR2554

Following is part of Solo: you see every change to SHR2554 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in